Tirzema
Generic Name
Tirzepatide
Manufacturer
XYZ Pharmaceuticals (hypothetical local manufacturer for 'Tirzema')
Country
Bangladesh (hypothetical)
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| tirzema 25 mg injection | ৳ 1,400.00 | N/A |
Description
Overview of the medicine
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated for improving glycemic control in adults with type 2 diabetes mellitus and for chronic weight management.
Uses & Indications
Dosage
Adults
Initial dose is 2.5 mg subcutaneously once weekly. After 4 weeks, the dose should be increased to 5 mg once weekly. The dose may be further increased in 2.5 mg increments after at least 4 weeks on the current dose. The maximum recommended dose is 15 mg once weekly.
Elderly
No dosage adjustment is required based on age.
Renal_impairment
No dosage adjustment is required for patients with mild to severe renal impairment or end-stage renal disease. Exercise caution in patients with end-stage renal disease receiving dialysis, as clinical experience is limited.
How to Take
Administer subcutaneously once weekly at any time of day, with or without meals. Inject into the abdomen, thigh, or upper arm. Rotate injection sites with each dose.
Mechanism of Action
Tirzepatide mimics the effects of endogenous GIP and GLP-1, enhancing glucose-dependent insulin secretion, suppressing glucagon secretion, slowing gastric emptying, and reducing food intake, leading to improved glycemic control and weight loss.
Pharmacokinetics
Onset
Clinical effects are typically observed within weeks of initiation.
Excretion
Metabolic degradation products are primarily excreted via urine and feces.
Half life
The elimination half-life is approximately 5 days, supporting once-weekly dosing.
Absorption
Administered subcutaneously, tirzepatide reaches peak plasma concentration in 24 to 48 hours.
Metabolism
Primarily metabolized via proteolysis, peptide bond cleavage, and beta-oxidation of the fatty diacid moiety. It is not significantly metabolized by cytochrome P450 (CYP) enzymes.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to tirzepatide or any component of the product.
Drug Interactions
Oral Contraceptives
May decrease efficacy of oral contraceptives due to delayed gastric emptying. Advise alternative contraception or additional barrier methods for 4 weeks after initiation and each dose escalation.
Drugs with narrow therapeutic index
Potential for altered absorption due to delayed gastric emptying. Monitor closely.
Insulin Secretagogues (Sulfonylureas) / Insulin
Increased risk of hypoglycemia when coadministered. May require dose reduction of sulfonylureas or insulin.
Storage
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. If needed, the pen can be stored at room temperature (up to 30°C/86°F) for a maximum of 21 days.
Overdose
In the event of an overdose, symptomatic and supportive treatment is recommended. Due to the long half-life, prolonged observation and treatment may be needed.
Pregnancy & Lactation
Limited data on tirzepatide use in pregnant women. Use only if potential benefit justifies potential risk to fetus. It is unknown if tirzepatide is excreted in human milk; consider benefits vs. risks.
Side Effects
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Known hypersensitivity to tirzepatide or any component of the product.
Drug Interactions
Oral Contraceptives
May decrease efficacy of oral contraceptives due to delayed gastric emptying. Advise alternative contraception or additional barrier methods for 4 weeks after initiation and each dose escalation.
Drugs with narrow therapeutic index
Potential for altered absorption due to delayed gastric emptying. Monitor closely.
Insulin Secretagogues (Sulfonylureas) / Insulin
Increased risk of hypoglycemia when coadministered. May require dose reduction of sulfonylureas or insulin.
Storage
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. If needed, the pen can be stored at room temperature (up to 30°C/86°F) for a maximum of 21 days.
Overdose
In the event of an overdose, symptomatic and supportive treatment is recommended. Due to the long half-life, prolonged observation and treatment may be needed.
Pregnancy & Lactation
Limited data on tirzepatide use in pregnant women. Use only if potential benefit justifies potential risk to fetus. It is unknown if tirzepatide is excreted in human milk; consider benefits vs. risks.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Check individual product packaging, typically 2-3 years when stored correctly.
Availability
Worldwide, pharmacies
Approval Status
FDA Approved
Patent Status
Patented by Eli Lilly and Company
Clinical Trials
Tirzepatide has been extensively studied in large-scale Phase 3 clinical trials (SURPASS and SURMOUNT programs) demonstrating significant efficacy in glycemic control and weight loss.
Lab Monitoring
- Glycemic control (HbA1c, fasting glucose)
- Renal function (eGFR) in patients at risk
- Thyroid function (if concerns for MTC)
- Amylase/lipase (if pancreatitis is suspected)
Doctor Notes
- Educate patients on proper injection technique and site rotation to minimize local reactions.
- Advise patients on managing common gastrointestinal side effects (e.g., nausea, vomiting, diarrhea) and to stay adequately hydrated.
- Screen patients for personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) before initiating treatment.
Patient Guidelines
- Administer once weekly as directed by your doctor.
- Rotate injection sites to prevent skin reactions.
- Report any severe abdominal pain, with or without vomiting, which may be a symptom of pancreatitis.
- Monitor for signs of hypoglycemia, especially if also using insulin or sulfonylureas.
- Discuss your personal or family history of thyroid cancer with your doctor.
Missed Dose Advice
If a dose is missed and the next scheduled dose is 4 days or more away, administer the missed dose as soon as possible. If less than 4 days until the next scheduled dose, skip the missed dose and resume with the next regularly scheduled dose.
Driving Precautions
Tirzepatide has no or negligible influence on the ability to drive and use machines. However, patients should be advised of the risk of hypoglycemia when used in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin, which may affect the ability to drive or use machines.
Lifestyle Advice
- Continue diet and exercise as advised by your healthcare provider to maximize benefits.
- Stay well-hydrated, especially if experiencing gastrointestinal side effects.
- Maintain regular follow-up appointments with your doctor to monitor your progress and manage any side effects.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Tirzema Brand
Other medicines available under the same brand name
